These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 19369008)

  • 1. How powerful is CD133 as a cancer stem cell marker in brain tumors?
    Cheng JX; Liu BL; Zhang X
    Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Isolation and characterization of brain tumor stem cells in human medulloblastoma].
    Li MC; Deng YW; Wu J; Chen FH; Liu JF; Fang JS
    Ai Zheng; 2006 Feb; 25(2):241-6. PubMed ID: 16480595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation research between cancer stem cells and the pathological grades of neuroepithelial tumors].
    Deng YW; Fang JS; Li MC; Chen FH; Zhou XY; Wu J; Zhou RH; Fang F; Chen C; Lu M; Zeng FY
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):45-51. PubMed ID: 16562674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer stem cells in the central nervous system--a critical review.
    Prestegarden L; Enger PØ
    Cancer Res; 2010 Nov; 70(21):8255-8. PubMed ID: 20959482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
    Song WC; Fei XF; Dong J
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastoma cancer stem cells--from concept to clinical application.
    Stopschinski BE; Beier CP; Beier D
    Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
    Kelly JJ; Stechishin O; Chojnacki A; Lun X; Sun B; Senger DL; Forsyth P; Auer RN; Dunn JF; Cairncross JG; Parney IF; Weiss S
    Stem Cells; 2009 Aug; 27(8):1722-33. PubMed ID: 19544433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
    Li MW; Niu CS
    Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD133 as a marker for cancer stem cells: progresses and concerns.
    Wu Y; Wu PY
    Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD133 antigen in cancer.
    Ferrandina G; Petrillo M; Bonanno G; Scambia G
    Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limits of CD133 as a marker of glioma self-renewing cells.
    Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I
    Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
    Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
    Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
    Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
    Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
    Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
    Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progression of CD133 as a marker of cancer stem cells.
    Zhang H; Li SY
    Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
    Shin JH; Lee YS; Hong YK; Kang CS
    J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
    Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Investigation of CD133 as putative marker of tumor-initiating cell in laryngeal carcinoma].
    Wei XD; Zhou L; Cheng L; Tian J
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Sep; 42(9):692-6. PubMed ID: 18051573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
    Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
    Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro.
    Kahlert UD; Maciaczyk D; Dai F; Claus R; Firat E; Doostkam S; Bogiel T; Carro MS; Döbrössy M; Herold-Mende C; Niedermann G; Prinz M; Nikkhah G; Maciaczyk J
    J Neuropathol Exp Neurol; 2012 Dec; 71(12):1086-99. PubMed ID: 23147506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.